MiNK Therapeutics Q3 loss narrows due to lower professional fees and stock compensation
INKT•MiNK Therapeutics reported a Q3 net loss of $2.6 million, or $0.50 per share, with loss per share improving 23% year over year. The company recorded its first pre-commercial revenue from named-patient access and expects to begin US dosing in its ARDS trial before year-end 2026.
1. Quarterly results
MiNK Therapeutics reported a Q3 net loss of $2.6 million and a loss per share of $0.50, an improvement of 23% year over year. General and administrative expense fell 44%, mainly due to lower professional fees and stock compensation, while research and development expense rose with activity in its randomized Phase 2 trial and related analyses.
2. Revenue and trial plans
The company recorded initial pre-commercial revenue from agenT-797 supplied through named-patient access in multiple countries. MiNK expects to begin US dosing in its ARDS trial before year-end 2026 and plans to report comparative data from the randomized trial in the second half of 2027.
3. Program development
MiNK was selected for the ARPA-H BoSS program and intends to expand named-patient access to additional markets where regulations allow.
